博济医药
(300404)
| 流通市值：27.94亿 | | | 总市值：38.38亿 |
| 流通股本：2.81亿 | | | 总股本：3.86亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 584,317,656.85 | 361,448,457 | 138,861,747.84 | 742,019,124.54 |
| 营业收入 | 584,317,656.85 | 361,448,457 | 138,861,747.84 | 742,019,124.54 |
| 二、营业总成本 | 554,800,483.18 | 339,017,207.06 | 133,525,582.85 | 711,635,085.64 |
| 营业成本 | 415,847,176.08 | 250,680,746.54 | 96,368,429.87 | 516,629,157.81 |
| 税金及附加 | 5,374,166.84 | 3,362,885.66 | 1,206,376.71 | 6,914,185.11 |
| 销售费用 | 41,415,253.66 | 25,595,831.69 | 11,782,325.58 | 53,809,106 |
| 管理费用 | 52,257,776.08 | 35,509,416.35 | 14,529,635.19 | 70,633,027.32 |
| 研发费用 | 38,925,834.02 | 23,199,684.18 | 9,289,734.47 | 62,593,951.61 |
| 财务费用 | 980,276.5 | 668,642.64 | 349,081.03 | 1,055,657.79 |
| 其中:利息费用 | 1,249,884.25 | 901,597.45 | 509,095.34 | 3,186,407.41 |
| 其中:利息收入 | 413,797.57 | 316,426.73 | 205,526.25 | 2,300,564.7 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,312,070.54 | 914,273.99 | 490,581.85 | 1,058,690.69 |
| 加:投资收益 | 422,611.89 | 301,173.62 | 61,231.81 | 1,979,446.48 |
| 资产处置收益 | - | - | - | -213,678.75 |
| 资产减值损失(新) | -6,434,398.97 | -4,518,309.7 | -1,199,977.4 | -6,349,010.26 |
| 信用减值损失(新) | -13,636,718.7 | -8,848,206.87 | -3,344,588.25 | -17,543,157.35 |
| 其他收益 | 7,428,366.12 | 3,732,202.32 | 2,560,044.7 | 9,270,391.91 |
| 四、营业利润 | 18,609,104.55 | 14,012,383.3 | 3,903,457.7 | 18,586,721.62 |
| 加:营业外收入 | 2,224.58 | 1,932.3 | 11.85 | 44,805.46 |
| 减:营业外支出 | 280,696.32 | 160,392.36 | 60,381.7 | 212,030.13 |
| 五、利润总额 | 18,330,632.81 | 13,853,923.24 | 3,843,087.85 | 18,419,496.95 |
| 减:所得税费用 | -5,536,883.38 | -3,706,505.86 | -837,653.21 | -12,237,970.27 |
| 六、净利润 | 23,867,516.19 | 17,560,429.1 | 4,680,741.06 | 30,657,467.22 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 23,867,516.19 | 17,560,429.1 | 4,680,741.06 | 30,657,467.22 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 21,913,904.3 | 15,569,864.27 | 3,900,579.72 | 28,776,806.52 |
| 少数股东损益 | 1,953,611.89 | 1,990,564.83 | 780,161.34 | 1,880,660.7 |
| 扣除非经常损益后的净利润 | 14,981,173.93 | 11,988,298.74 | 1,697,920.67 | 19,304,628.89 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.04 | 0.01 | 0.08 |
| (二)稀释每股收益 | 0.06 | 0.04 | 0.01 | 0.08 |
| 八、其他综合收益 | -395,881.93 | -138,760.48 | -82,948.74 | 519,743.78 |
| 归属于母公司股东的其他综合收益 | -391,976.91 | -137,183.38 | -82,366.48 | 513,436.7 |
| 九、综合收益总额 | 23,471,634.26 | 17,421,668.62 | 4,597,792.32 | 31,177,211 |
| 归属于母公司股东的综合收益总额 | 21,521,927.39 | 15,432,680.89 | 3,818,213.24 | 29,290,243.22 |
| 归属于少数股东的综合收益总额 | 1,949,706.87 | 1,988,987.73 | 779,579.08 | 1,886,967.78 |
| 公告日期 | 2025-10-29 | 2025-08-27 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |